According to Wuzhou Medical's announcement, the first half of 2026 achieved operating income of 203 million yuan, a year-on-year decrease of 6.40%; net profit attributable to shareholders of listed companies was 15.3634 million yuan, an increase of 46.11%; after deducting non-net profit of 10.9049 million yuan, an increase of 30.77% year-on-year. Due to the company's plans to issue shares and pay cash to purchase assets, stock trading was suspended from the opening of the market on July 8, 2026, and resumed trading on July 22. During the reporting period, no cash dividends will be distributed, bonus shares will not be given, and capital will not be transferred from the Provident Fund.

According to Wuzhou Medical's announcement, the first half of 2026 achieved operating income of 203 million yuan, a year-on-year decrease of 6.40%; net profit attributable to shareholders of listed companies was 15.3634 million yuan, an increase of 46.11%; after deducting non-net profit of 10.9049 million yuan, an increase of 30.77% year-on-year. Due to the company's plans to issue shares and pay cash to purchase assets, stock trading was suspended from the opening of the market on July 8, 2026, and resumed trading on July 22. During the reporting period, no cash dividends will be distributed, bonus shares will not be given, and capital will not be transferred from the Provident Fund.